- Home
- AGIO vs BMEZ Comparison
AGIO vs BMEZ Comparison
Compare AGIO & BMEZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BMEZ
- Stock Information
- Founded
- AGIO 2007
- BMEZ N/A
- Country
- AGIO United States
- BMEZ United States
- Employees
- AGIO N/A
- BMEZ N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BMEZ Trusts Except Educational Religious and Charitable
- Sector
- AGIO Health Care
- BMEZ Finance
- Exchange
- AGIO Nasdaq
- BMEZ Nasdaq
- Market Cap
- AGIO 1.4B
- BMEZ 1.5B
- IPO Year
- AGIO 2013
- BMEZ N/A
- Fundamental
- Price
- AGIO $33.97
- BMEZ $14.48
- Analyst Decision
- AGIO Buy
- BMEZ
- Analyst Count
- AGIO 6
- BMEZ 0
- Target Price
- AGIO $58.60
- BMEZ N/A
- AVG Volume (30 Days)
- AGIO 529.1K
- BMEZ 391.3K
- Earning Date
- AGIO 07-31-2025
- BMEZ 01-01-0001
- Dividend Yield
- AGIO N/A
- BMEZ 8.71%
- EPS Growth
- AGIO N/A
- BMEZ N/A
- EPS
- AGIO 11.45
- BMEZ 0.54
- Revenue
- AGIO $37,035,000.00
- BMEZ N/A
- Revenue This Year
- AGIO $22.30
- BMEZ N/A
- Revenue Next Year
- AGIO $219.19
- BMEZ N/A
- P/E Ratio
- AGIO $3.00
- BMEZ $30.17
- Revenue Growth
- AGIO 25.96
- BMEZ N/A
- 52 Week Low
- AGIO $23.42
- BMEZ $12.93
- 52 Week High
- AGIO $62.58
- BMEZ $16.95
- Technical
- Relative Strength Index (RSI)
- AGIO 52.40
- BMEZ 51.66
- Support Level
- AGIO $32.53
- BMEZ $14.11
- Resistance Level
- AGIO $34.34
- BMEZ $14.79
- Average True Range (ATR)
- AGIO 1.28
- BMEZ 0.18
- MACD
- AGIO -0.31
- BMEZ -0.01
- Stochastic Oscillator
- AGIO 20.98
- BMEZ 54.41
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.